David Campbell, Ph.D.

Chief Scientific Officer, Small Molecules

David Campbell has over 15 years of industry experience in drug discovery and development focused on oncology and CNS applications of proprietary PAK inhibitors, anti-bacterial drugs, kinase inhibitors, obesity, osteoporosis, and diabetes.

He currently serves as chief scientific officer, small molecules, at COI Pharmaceuticals and is an entrepreneur in residence at Avalon Ventures. Dr. Campbell has served as the interim Chief Scientific Officer of RQx, an Avalon portfolio company, that developed novel anti-bacterial drugs and was partnered with Genentech. Dr. Campbell served as a member of the Phenomix executive team since 2003, most recently as an executive officer and senior vice president, discovery and development with responsibility for all drug discovery and development through early clinical trials to human proof of concept. Under his leadership, a DPP4 inhibitor (Dutogliptin) for the treatment of Type 2 diabetes was developed through a successful Phase 3 clinical trial, and an NS3 protease inhibitor for the treatment of Hepatitis C was discovered and developed through Phase 1. He was a member of the executive team that raised a total of $95M in two venture rounds, and successfully partnered Dutogliptin North American rights to Forest Laboratories and European rights to Chiesi Farmaceutici. Dr. Campbell was the Senior Vice President of Chemical Sciences at ActivX Biosciences from 2001 to 2003, where he directed the company’s internal drug discovery programs as well as the development of ActivX-sactivity-based chemical probes for labeling and capturing members of several key protein families, most notably the kinase family. From April 1998 to April 2001, Dr. Campbell was Director of Discovery Chemistry at Bayer Corporation where he directed the research efforts of the 41-scientist group. Dr. Campbell began his career at Affymax Research Institute, a combinatorial chemistry company that was purchased by Glaxo Wellcome in 1995 for $533M. As Director his group’s focus was designing libraries targeting proteases and to optimize leads that were identified.

Dr. Campbell received post-doctoral training under then University of California, Berkeley professor, Dr. Peter Schultz. He has a Ph.D. in organic chemistry from Cornell University and a B.S. in chemistry from Harvey Mudd College.


in the news

  • Avalon Ventures and COI Pharmaceuticals Announce Acquisition of Sitari Pharmaceuticals by GSK

    read more
  • A Minute for Celiac Disease

    read more
  • COI’s Focus on Rare Disease

    read more